The Effect of Lactobacillus plantarum 299v on the Incidence of Clostridium difficile Infection in High Risk Patients Treated with Antibiotics

Agata Kujawa-Szewieczek, Marcin Adamczak, Katarzyna Kwiecień, Sylwia Dudzicz, Magdalena Gazda, Andrzej Więcek, Agata Kujawa-Szewieczek, Marcin Adamczak, Katarzyna Kwiecień, Sylwia Dudzicz, Magdalena Gazda, Andrzej Więcek

Abstract

Background: Lactobacillus plantarum 299v (LP299v) has been used in order to reduce gastrointestinal symptoms during antibiotic exposure. However, it remains controversial whether or not probiotics are effective in the prevention of Clostridium difficile infections (CDI) among patients receiving antibiotics. The aim of this study was to analyze the CDI among patients receiving antibiotics and hospitalized in the period before and after starting routine use of LP299v as a prevention of this infection.

Methods: Among 3533 patients hospitalized in the nephrology and transplantation ward during a two-year period, 23 patients with CDI were diagnosed and enrolled in this retrospective study. Since November 2013, prevention of CDI with oral use of LP299v was performed in all patients treated with antibiotics and who were at a high risk of developing CDI. The observation period was divided into two twelve-month intervals before and after initiation of the use of LP299v as a prophylactic against CDI.

Results: A significant (p = 0.0001) reduction of the number of cases of CDI was found after routinely using LP299v (n = 2; 0.11% of all hospitalized patients) compared with the previous twelve-month period of observation (n = 21; 1.21% of all hospitalized patients).

Conclusions: Routine use of LP299v during treatment with antibiotics may prevent C. difficile infection in the nephrology and transplantation ward.

Keywords: Clostridium difficile; Lactobacillus plantarum 299v; kidney and pancreas transplantation; kidney transplantation; liver transplantation; nephrology and transplantation ward.

Figures

Figure 1
Figure 1
The incidence of CDI before and after administration of Lactobacillus plantarum 299v (LP299v).
Figure 2
Figure 2
The antibiotic exposure in the CDI patients.

References

    1. Barbut F., Petit J.C. Epidemiology of Clostridium difficile-associated infections. Clin. Microbiol. Infect. 2001;7:405–410. doi: 10.1046/j.1198-743x.2001.00289.x.
    1. Keven K., Basu A., Re L., Tan H., Marcos A., Fung J.J., Starzl T.E., Simmons R.L. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl. Infect. Dis. 2004;6:10–14. doi: 10.1111/j.1399-3062.2004.00040.x.
    1. Niemczyk M., Leszczyński P., Wyzgał J., Paczek L., Krawczyk M., Luczak M. Infections caused by Clostridium difficile in kidney or liver graft recipients. Ann. Transplant. 2005;10:70–74.
    1. Khanna S., Pardi D.S. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert. Rev. Gastroenterol. Hepatol. 2010;4:409–416. doi: 10.1586/egh.10.48.
    1. Noblett S.E., Welfare M., Seymore K. The role of surgery in Clostridium difficile colitis. Br. Med. J. 2009;338:1563. doi: 10.1136/bmj.b1563.
    1. Pépin J., Valiquette L., Alary M.E., Villemure P., Pelletier A., Forget K., Pepin K., Chouinard D. Clostridium difficile associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ. 2004;171:466–472. doi: 10.1503/cmaj.1041104.
    1. Fakety R., McFarland L.V., Surowicz C.M., Greenberg R.N., Elmer G.W., Mulligan M.E. Recurrent C. Recurrent Clostridium difficile diarrhoea: Characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 1997;24:324–333. doi: 10.1093/clinids/24.3.324.
    1. Olsen M.A., Yan Y., Reske K.A., Zilberberg M.D., Dubberke E.R. Recurrent Clostridium difficile infection is associated with increased mortality. Clin. Microbiol. Infect. 2015;21:164–170. doi: 10.1016/j.cmi.2014.08.017.
    1. Albright J.B., Bonatti H., Mendez J., Kramer D., Stauffer J., Hinder R., Michel J.A., Dickson R.C., Huqhes C., Nquyen J., et al. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl. Int. 2007;20:856–866. doi: 10.1111/j.1432-2277.2007.00530.x.
    1. Apaydin S., Altiparmak M.R., Saribas S., Ozturk R. Prevalence of Clostridium difficile toxin in kidney transplant recipients. Scand. J. Infect. Dis. 1998;30:542.
    1. Dubberke E.R., Riddle D.J. Clostridium difficile in solid organ transplant recipients. Am. J. Transpl. 2009;9:35–40. doi: 10.1111/j.1600-6143.2009.02891.x.
    1. Goldenberg J.Z., Ma S.S., Saxton J.D., Martzen M.R., Vandvik P.O., Thorlund K., Guyatt G.H., Johnston B.C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev. 2013:31–35. doi: 10.1002/14651858.CD006095.pub3.
    1. Allen S.J., Wareham K., Wang D., Bradley C., Hutchings H., Harris W., Dhar A., Brown H., Foden A., Gravenor M.B., et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382:1249–1257. doi: 10.1016/S0140-6736(13)61218-0.
    1. Daneman D. A probiotic trial: tipping the balance of evidence? Lancet. 2013;382:1228–1230. doi: 10.1016/S0140-6736(13)61571-8.
    1. Molin G., Jeppsson B., Ahrné S., Johansson M.L., Nobaek S., Ståhl M., Bengmark S. Numerical taxonomy of Lactobacillus spp. associated with healthy and diseased mucosa of the human intestines. J. Appl. Bacteriol. 1993;74:314–323. doi: 10.1111/j.1365-2672.1993.tb03031.x.
    1. Johansson M.L., Molin G., Jeppsson B., Nobaek S., Ahrné S., Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: In vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl. Environ. Microbiol. 1993;59:15–20.
    1. Ahrné S., Nobaek S., Jeppsson B., Adlerberth I., Wold A., Molin G. The normal Lactobacillus flora of healthy human rectal and oral mucosa. J. Appl. Microbiol. 1998;85:88–94. doi: 10.1046/j.1365-2672.1998.00480.x.
    1. Gross G., Snel J., Boekhorst J., Smits M.A., Kleerebezem M. Biodiversity of mannose-specific adhesion in Lactobacillus plantarum revisited: Strain-specific domain composition of the mannose-adhesin. Benef. Microbes. 2010;1:61–66. doi: 10.3920/BM2008.1006.
    1. Glenting J., Beck H.C., Vrang A., Riemann H., Ravn P., Hansen A.M., Antonsson M., Ahrné S., Israelsen H., Madsen S. Anchorless surface associated glycolytic enzymes from Lactobacillus plantarum 299v bind to epithelial cells and extracellular matrix proteins. Microbiol. Res. 2013;168:245–253. doi: 10.1016/j.micres.2013.01.003.
    1. Adawi D., Kasravi F.B., Molin G., Jeppsson B. Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model. Hepatology. 1997;25:642–647. doi: 10.1002/hep.510250325.
    1. Osman N., Adawi D., Ahrne S., Jeppsson B., Molin G. Probiotic strains of Lactobacillus and Bifidobacterium affect the translocation and intestinal load of Enterobacteriaceae differently after d-galactose-induced liver injury in rats. Microb. Ecol. Health Dis. 2005;17:40–46. doi: 10.1080/08910600510028433.
    1. Mangell P., Lennernäs P., Wang M., Olsson C., Ahrné S., Molin G., Thorlacius H., Jeppsson B. Adhesive capability of L plantarum 299v is important for preventing bacterial translocation in endotoxaemic rats. APMIS. 2006;114:611–618. doi: 10.1111/j.1600-0463.2006.apm_369.x.
    1. Mangiante G., Colucci G., Canepari P., Bassi C., Nicoli N., Casaril A., Marinello P., Bengmark S. Lactobacillus plantarum reduces infection of pancreatic necrosis in experimental acute pancreatitis. Digest. Surg. 2001;18:47–50. doi: 10.1159/000050096.
    1. McCracken V.J., Chun T., Baldeón M.E., Ahrné S., Molin G., Mackie R.I., Gaskins H.R. TNF-α sensitizes HT-29 colonic epithelial cells to intestinal lactobacilli. Exp. Biol. Med. 2002;227:665–670.
    1. Jacobsen C.N., Rosenfeldt-Nielsen V., Hayford A.E., Moller P.L., Michaelsen K.F., Poerregaard A., Sandstróm B., Tvede M., Jakobsen M. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl. Environ. Microbiol. 1999;65:4949–4956.
    1. Hiitt P., Shchepetova I., Loivukene K., Kullisaar T., Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and urpathogens. J. Appl. Microbiol. 2006;100:1324–1332. doi: 10.1111/j.1365-2672.2006.02857.x.
    1. Mack D.R., Michail S., Wei S., McDougall L., Hollingsworth M.A. Probiotics inhibit enteropathogenic E.coli adherence in vitro by inducing intestinal mucin gene expression. Am. J. Physiol. 1999;276:941–950.
    1. Michail S., Abernathy F. Lactobacillus plantarum reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic Escherichia coli infection. J. Pediatr. Gastroenterol. Nutr. 2002;35:350–355. doi: 10.1097/00005176-200209000-00021.
    1. Nobaek S., Johansson M.L., Molin G., Ahrné S., Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2000;95:1231–1238. doi: 10.1111/j.1572-0241.2000.02015.x.
    1. Niedzielin K., Kordecki H., Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome. Eur. J. Gastroenterol. Hepatol. 2001;13:1143–1147. doi: 10.1097/00042737-200110000-00004.
    1. Lönnermark E., Friman V., Lappas G., Sandberg T., Berggren A., Adlerberth I. Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J. Clin. Gastroenterol. 2010;44:106–112. doi: 10.1097/MCG.0b013e3181b2683f.
    1. Wullt M., Hagslätt M.L., Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: A double-blind, placebo-controlled trial. Scand. J. Infect. Dis. 2003;35:365–367. doi: 10.1080/00365540310010985.
    1. Klarin B., Wullt M., Palmquist I., Molin G., Larsson A., Jeppsson B. Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol. Scand. 2008;52:1096–1102. doi: 10.1111/j.1399-6576.2008.01748.x.
    1. Wullt M., Johansson Hagslätt M.L., Odenholt I., Berggren A. Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. Dig. Dis. Sci. 2007;52:2082–2086. doi: 10.1007/s10620-006-9123-3.
    1. Debast S.B., Bauer M.P., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 2014;20:1–26.
    1. Johansson M.L., Nobaek S., Berggren A., Nyman M., Björck I., Ahrné S., Jeppsson B., Molin G. Survival of Lactobacillus plantarum DSM 9843 (299v), and effect on the short-chain fatty acid content of faeces after ingestion of a rose-hip drink with fermented oats. Int. J. Food Microbiol. 1998;42:29–38. doi: 10.1016/S0168-1605(98)00055-5.
    1. Mortensen P.B., Clausen M.R. Short-chain fatty acids in the human colon: Relation to gastrointestinal health and disease. Scand. J. Gastroenterol. Suppl. 1996;216:132–148. doi: 10.3109/00365529609094568.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj